CCL25 and neoplasm: The authors proposed a novel immune evasion mechanism used by tumor cells, where the manipulation ofchemokine/chemokine receptor axis seems to represent a limiting mechanism for anti-tumoral immune response, as increased expression of CCL25 (CCR9 ligand) surrounding CRC epithelium and downregulation of intratumoral CCL25 prevent the entry of cytotoxic CCR9 CD8+ T cells into the tumor [29].